Meeting
2018 ASCO Annual Meeting
An investigator initiated multicenter phase I/II study of paclitaxel, ramucirumab with nivolumab as the second-line treatment in patients with metastatic gastric cancer.
Authors
Tomohiro Nishina
Shikoku Cancer Center, Matsuyama, Japan
Tomohiro Nishina , Shuichi Hironaka , Shigenori Kadowaki , Takeharu Yamanaka , Takako Eguchi Nakajima
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Esophageal or Gastric Cancer
Clinical Trial Registration Number
UMIN000025947
Citation
J Clin Oncol 36, 2018 (suppl; abstr TPS4131)
DOI
10.1200/JCO.2018.36.15_suppl.TPS4131
Abstract #
TPS4131
Poster Bd #
320a
Abstract Disclosures
Similar Posters
Poster
2020 Gastrointestinal Cancers Symposium
A phase I/II study of nivolumab, paclitaxel, and ramucirumab as second-line in advanced gastric cancer.
First Author: Shuichi Hironaka
Poster
2018 ASCO Annual Meeting
FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab for patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction as second-line therapy – the RAMIRIS Study.
First Author: Sylvie Lorenzen
Poster
2022 ASCO Gastrointestinal Cancers Symposium
A randomized phase II trial of paclitaxel plus ramucirumab versus nab-paclitaxel plus ramucirumab for gastric cancer with peritoneal dissemination refractory to first-line therapy (WJOG10617G/P-SELECT).
First Author: Kenro Hirata
Poster
2020 Gastrointestinal Cancers Symposium
Efficacy and safety of nab-paclitaxel plus ramucirumab versus paclitaxel plus ramucirumab as second-line treatment for patients with advanced gastric cancer: A single institutional experience.
First Author: Mashiro Okunaka